An 8-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 80 mg and; Amlodipine 10mg Versus Telmisartan 80 mg Monotherapy or Amlodipine 10 mg Monotherapy as First Line Therapy in Patients With Severe Hypertension (Grade 3).

Trial Profile

An 8-week Randomised, Double-blind Study to Compare the Fixed-dose Combination of Telmisartan 80 mg and; Amlodipine 10mg Versus Telmisartan 80 mg Monotherapy or Amlodipine 10 mg Monotherapy as First Line Therapy in Patients With Severe Hypertension (Grade 3).

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2013

At a glance

  • Drugs Amlodipine; Amlodipine/telmisartan; Telmisartan
  • Indications Essential hypertension; Hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms TEAMSTA Severe HTN
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 24 Mar 2012 This trial is recruiting in Spain, Hungary and France.
    • 13 Oct 2010 A Boehringer Ingelheim media release states the EMEA has approved telmisartan/amlodipine for the treatment of hypertension in adults.
    • 31 Aug 2010 Results from this trial, presented at the 20th Scientific Society of Hypertension, were discussed at a briefing in Stockholm according to a Boehringer Ingelheim media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top